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PURPOSE: To evaluate the feasibility and effectiveness of transcatheter embolization by forcible 
intra-arterial injection of ethylene vinyl alcohol copolymer (EVAL)/ethanol mixture under micro-
balloon occlusion in comparison with conventional transcatheter arterial embolization methods in 
non-tumoral swine liver. 
MATERIALS AND METHODS: Nine swine were divided into three groups: embolization with 
EVAL/ethanol mixture (EVAL group, n=5), with ethiodized oil (ethiodized oil group, n=2) and 
with microspheres (microspheres group, n=2). Embolization was performed at the subsegmental 
hepatic artery. EVAL/ethanol mixture was injected forcibly through a microcatheter with a balloon, 
which was inflated to prevent backflow of the mixture during the injection. Ethiodized oil or 
microspheres were injected into the artery using a microcatheter without balloon occlusion. Two 
animals of the EVAL group were euthanized immediately after embolization, and the distribution of 
EVAL was assessed microscopically. The remaining seven animals were euthanized four weeks 
after embolization, and the histopathological changes were assessed. 
RESULTS: All procedures were technically successful. EVAL occupied greater than 80% of the 
embolized hepatic arterial, portal venous and sinusoidal lumens. Four weeks after embolization, 
ischemic coagulation necrosis was observed in the EVAL group. In the ethiodized oil and 
microspheres groups, parenchymal necrosis was not observed.  
CONCLUSION: Transcatheter embolization by forcible intra-arterial injection of EVAL/ethanol 
mixture under micro-balloon occlusion was feasible and achieved the simultaneous embolization of 





 Transcatheter arterial embolization (TAE) is an effective therapeutic option for 
hepatocellular carcinoma (HCC)(1, 2, 3). However, local recurrence often occurs due to insufficient 
embolization of tumor and surrounding vessels (2, 3, 4). In hypervascular HCCs, the blood supply 
from feeding hepatic arteries drains into the surrounding portal venules and hepatic sinusoids which 
communicate with tumor blood sinusoids (5, 6, 7). It has been speculated that particulate TAE often 
allows the peripheral portion of the HCC to survive probably due to reversed blood flow from the 
hepatic sinusoids and/or portal venules surrounding the tumor. A theoretical advantage of using a 
liquid agent such as ethiodized oil (Lipiodol, Andre Guerbet, Aulnay-sous-Bois, France) for 
embolization of hypervascular HCCs is its tendency to flow into the peritumoral portal vein or 
surrounding hepatic sinusoids through the peribiliary plexus (PBP) (3, 8, 9, 10) and drainage routes 
from the tumor (7). However, the embolization effect of ethiodized oil is often temporary and thus 
insufficient (3, 11).  
 Ethylene vinyl alcohol copolymer dissolved in dimethyl sulfoxide (Onyx LES, ev3 
endovascular, Inc., Plymouth MA) represents a widely used permanent liquid embolic agent (12). 
However, because dimethyl sulfoxide has shown vascular toxicity when injected rapidly (13), a 
mixture of ethylene vinyl alcohol copolymer and ethanol (EVAL/ethanol mixture) was developed 
by Hamada et al. and has been used for the embolization of arteriovenous malformations with 
favorable clinical results (14, 15). This EVAL/ethanol mixture has a nonadhesive property and is a 
completely liquid material that can therefore be injected forcibly through a microcatheter. Because 
of this unique feature, it is theoretically possible to embolize the hepatic artery, tumor blood 
sinusoids, portal vein and hepatic sinusoids simultaneously by forcible intra-arterial injection of the 
EVAL/ethanol mixture using balloon occlusion, possibly resulting in complete infarction of the 
tumor and surrounding parenchyma (transcatheter ablation). The purpose of this study was to 
experimentally evaluate the feasibility and effectiveness of transcatheter embolization by forcible 
intra-arterial injection of EVAL/ethanol mixture under micro-balloon occlusion in comparison with 
conventional TAE in non-tumoral swine liver. 
 




 Nine swine (Landrace Large White and Duroc) that weighed 38-45 kg each were used in 
this study. All experiments were performed after permission was obtained from the Animal 
Experimentation Ethical Committee of Kanazawa University and according to the Animal Care 




 EVAL/ethanol mixture is comprised of 4 g ethylene vinyl alcohol copolymer (EVAL) 
dissolved in 60 g iopamidol with an iodine concentration of 300 mg/ml (Iopamiron, Bayer Yakuhin, 
Osaka, Japan) and 36 g of 96 % ethanol as described previously (14). The EVAL consists of a 0.68-
mol fraction of vinyl alcohol and a 0.32-mol fraction of ethylene, and its degree of polymerization 
is 1100. The EVAL can be dissolved easily in the iopamidol/ethanol mixture by heating the 
components to 80 degrees centigrade for 30 minutes. After the EVAL is completely dissolved, the 
mixture is sterilized for 20 minutes in a steam autoclave (121 ℃ at 11 Pa). Before use, the 
EVAL/ethanol mixture is re-warmed to 80 degrees centigrade for at least five minutes because 
EVAL precipitates at room temperature. Once the precipitate dissolves, EVAL remains in a 
dissolved state for at least two hours. The mixture has a low viscosity of 33.2 to 35.1 centipoise at 
37 ℃. When the EVAL/ethanol mixture contacts with a larger amount of blood (in larger vessels), 
EVAL precipitates rapidly and forms a sponge-like cast, while in smaller vessels precipitation 
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occurs only gradually (14). The EVAL/ethanol mixture was provided by Hamada et al. (14) who 
originally developed this material. It was reheated immediately before embolization. 
 In this study, two other embolic agents were used, namely ethiodized oil, and microspheres 
(Bead Block 100-300 um, Terumo Europe Interventional Systems, Leuven, Belgium). The 
microspheres were mixed with a contrast agent (Imagenil 300, Terumo) in accordance with the 
instructions for use. The purpose of this study was to evaluate the embolization effect of forcible 
intra-arterial injection of EVAL/ethanol mixture under micro-balloon occlusion in comparison with 
conventional TAE methods, and was not to explore the most effective embolic agents to evoke 
segmental infarction in the liver by the forcible injection of various kinds of embolic agents under 
micro-balloon occlusion. Therefore, simple intra-arterial injection of ethiodized oil and 




 The animals were divided into three groups according to the TAE method used: 
embolization with EVAL/ethanol mixture (EVAL group, n=5), in which TAE was performed by 
forcible intra-arterial injection of EVAL/ethanol mixture under micro-balloon occlusion; 
embolization only with ethiodized oil (ethiodized oil group, n=2) and only with microspheres 
(microspheres group, n=2), both without balloon occlusion. 
 All animals were placed under general anesthesia after sedation with an intramuscular 
injection of azaperone (4 mg/kg), atropin sulfate (0.05 mg/kg), and ketamine hydrochloride (15 
mg/kg). Anesthesia was induced with a nitrous oxide (2 L), oxygen (2 L), and 5 % sevoflurance 
mixture by inhalation. An endotracheal tube was inserted to maintain the anesthesia. Pancuronium 
bromide (0.1 mg/kg) was administered intravenously for muscle relaxation. Monitoring consisted of 
electrocardiography, invasive blood pressure measurements, and percutaneous recording of oxygen 
saturation.  
 The right femoral artery was surgically exposed, and a 6-F guiding sheath (Destination, 
Terumo, Tokyo, Japan) was introduced by direct puncture. Baseline arteriography of the celiac 
trunk, common hepatic artery and arterial portography via the superior mesenteric artery was 
performed with a 5-F Cobra shaped catheter (Terumo). The tip of the guiding sheath was then 
placed into the celiac trunk. 
 In all five animals of EVAL group, a 2.8-F tip microcatheter with a silicone balloon 
(IIGUMAN type C, Fuji Systems Corp, Tokyo, Japan) was placed into the subsegmental hepatic 
artery. A 0.012 inch guidewire (GT Wire, Terumo) was used to aid the microcatheter insertion. The 
silicone balloon of the microcatheter was inflated to prevent backflow during the forcible injection 
of the EVAL/ethanol mixture. The main lumen of the microcatheter was flushed with 30 % ethanol 
to prevent premature solidification of the EVAL/ethanol mixture. EVAL/ethanol mixture filling a 
2.5 ml syringe was injected forcibly through the main lumen of the microcatheter. The progress of 
the embolization procedure was controlled under fluoroscopic guidance. The embolization endpoint 
was complete filling of the hepatic artery distal to the balloon microcatheter. In this study, an 
average of 1.4±0.1 ml of 30% ethanol was injected before the mixture injection and with the 
mixture. 
 In all animals of the ethiodized oil and microspheres groups, a 2.3-F tip microcatheter 
(Progreat, Terumo) was placed into the subsegmental hepatic artery. A 0.018 inch guidewire (GT 
Wire, Terumo) was used to aid its insertion. In the ethiodized oil group (n=2), ethiodized oil filling 
a 2.5 ml syringe was injected through the microcatheter. In the microspheres group (n=2), 
microspheres filling a 2.5 ml syringe were injected through the microcatheter. The progress of the 
embolization procedure was controlled under fluoroscopic guidance. The embolization endpoint 
was determined as the point at which stasis of arterial blood flow or the portal vein was observed. 
 
Handling after embolization 
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 After embolization, celiac arteriography and arterial portography via the superior mesenteric 
artery were performed in all animals. Two animals of the EVAL group were euthanized 
immediately after the embolization procedure, and the livers were retrieved. The remaining seven 
animals were allowed to recover from anesthesia. The animals were monitored for fever and 
malaise during the follow-up period. Four weeks after embolization, the animals were placed under 
general anesthesia, and follow-up angiography was performed. In clinical practice, the impairment 
of liver function induced by TACE for HCC usually subsides around one month after TACE, and 
therefore four weeks’ follow up period was chosen in this experimental study. The animals were 
euthanized and their livers were retrieved. All specimens were fixed in 10% formaldehyde for at 
least a week. Sections were cut into thin slices and embedded in paraffin, and stained with 
hematoxylin and eosin for histopathological evaluation. It has been clarified that EVAL does not 




 One section from the central portion of the embolized segment including the proximal 
portion of the embolized segmental artery was subjected to the analysis. The numbers of hepatic 
arteries and portal veins filled with embolic materials were counted on the microscopic sections of 
four square centimeters near the embolized subsegmental hepatic artery at a magnification of 100 in 
the two animals of EVAL group euthanized immediately after embolization. Furthermore, the 
number of hepatic lobules in which embolic materials filled more than 80% of the sinusoid area was 
determined at the same site. The percentages of the embolized vessels and hepatic lobules were 
calculated by dividing the number of vessels and hepatic lobules filled with EVAL by the total 
number of those in the region of interest. In the four-week follow up animals (EVAL group: n=3, 
ethiodized oil group: n=2, microspheres group: n=2), the distribution of embolic material and the 




Overall Procedural Success 
 
 All procedures were successfully completed without technical difficulties. The 
microcatheter with a balloon was successfully introduced into the subsegmental hepatic artery in all 
EVAL group animals. No complications occurred during the procedure. No backflow of the 
EVAL/ethanol mixture through the balloon or extravasation of the mixture was observed. The 
blood pressure and oxygen saturation were stable during the embolization procedures in all animals. 




 The angiographic findings are summarized in Table 1. On the angiography performed 
immediately after TAE, both hepatic artery and portal vein in the embolized segments were 
occluded in the EVAL and ethiodized oil groups (Fig. 1, Fig. S1; available online). In contrast, in 
the microspheres group, only the hepatic artery was occluded with the portal vein remaining patent 
(Fig. S2; available online). On the angiography performed four weeks after TAE, recanalization of 
the embolized hepatic artery was not observed in the EVAL or microspheres groups but was in the 
ethiodized oil group. The portal vein in the embolized hepatic segment remained occluded in the 
EVAL group (Fig. 1), whereas it was restored in the ethiodized oil group (Fig. S1; available online). 
In the microspheres group, no change in portal vein visualization was observed either immediately 





 Macroscopically, the changes in the central portion of the embolized segments were 
homogeneous in the specimens of the two animals of the EVAL groups euthanized immediately 
after embolization. The EVAL was observed as a light gray material by light microscopy on 
hematoxylin-eosin staining. In the specimens of the two animals of EVAL group, more than 80 % 
of the entire lumens of the embolized hepatic arteries and portal veins were filled with EVAL (Fig. 
2). Furthermore, the EVAL material was observed in 80 % or more of the area of the sinusoids in 
the embolized segment (Table 2, Fig. 2). There was no evidence of perivascular hemorrhage or 
damage to the vessels wall.  
 Four weeks after embolization, in all of the three animals of EVAL group, the embolized 
segments were severely atrophic and capsular fibrosis was observed on gross pathology (Fig. 3). 
Microscopically, massive ischemic coagulation necrosis was observed in the embolized segment 
(Fig. 3). In one of these cases, EVAL was seen to fill the hepatic arteries, portal veins and sinusoids 
(Fig. 3), but it was difficult to identify in the other cases because of marked parenchymal necrosis 
and degeneration in the embolized segments. Parenchymal necrosis was not observed in any 
animals of the ethiodized oil or microspheres groups (Fig. S3; available online). Microspheres were 
observed only in the hepatic arteries, but not in the portal vein or sinusoids (Fig. S3; available 
online). Ethiodized oil was not observed in any specimens. Since the numbers of animals studied 
were small, a statistical analysis was not performed because of the reliability lowered. However, the 




 Nakao et al. previously reported that combined direct embolization of both hepatic artery 
and portal vein induced almost complete infarction of the obstructed segment of the liver and 
necrosis of HCC within it (16). However, this procedure has not been widely employed because of 
its extreme invasiveness. To achieve embolization of both hepatic artery and portal vein less 
invasively, superselective (subsegmental) TACE with ethiodized oil and gelatin sponge was 
developed in Japan but local HCC recurrence still occurs (3, 11). To overcome this problem, 
introduction of a new TAE technique for relatively small HCC was intended. The results of this 
study showed that the forcible intra-arterial injection of EVAL/ethanol mixture into a subsegmental 
hepatic artery under balloon occlusion was technically feasible, and caused marked parenchymal 
necrosis with simultaneous embolization of the hepatic arteries, portal veins and hepatic sinusoids. 
Generally speaking, to induce infarction in the liver is dangerous for clinical application, but it is 
well known that infarction in a limited area (subsegment, etc.) of the liver can be tolerated even in 
cirrhotic patients (3, 11, 16). 
 Microspheres have been used for transcatheter arterial chemoembolization (TACE) or bland 
embolization to treat advanced HCC (17, 18, 19). The previous study (20) and this study showed no 
evidence of obstruction of the portal vein and hepatic sinusoids or parenchymal necrosis after 
embolization with microspheres. Microspheres travel to the distal artery and embolize the 
peripheral arterioles with a diameter corresponding to the particle size with out portal vein 
obstruction as confirmed in this study. For this reason, insufficient embolization of HCC and 
surrounding liver mainly due to the remaining portal venous supply from the surrounding liver is 
expected resulting in a relatively high local recurrence rate of HCC following TAE therapy with 
microspheres (17, 18).  
 On the other hand, as mentioned above, ethiodized oil injected into the hepatic artery can 
flow into the portal venules and hepatic sinusoids through PBP but cannot remain in them 
sufficiently long to induce complete infarction of the liver (10). In this study, this was also 
reconfirmed. In clinical practice, during TAE therapy, ethiodized oil is very often observed to flow 
into the portal vein but gradually disappears on fluoroscopic observation. When a particulate 
embolic agent is injected followed by ethiodized oil injection, the speed of the disappearance of 
ethiodized oil from the portal vein becomes slow and may induce more severe infarction. However, 
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in subsegmental TAE for HCCs, the inflow of ethiodized oil into the portal veins is not always 
adequate probably depending on individual differences in the microangioarchitecture of the liver 
and tumors (11). 
 In this study, the EVAL/ethanol mixture was injected forcibly into the vessels under balloon 
occlusion to achieve embolization of all intrahepatic vessels including hepatic arterioles, portal 
venules and hepatic sinusoids resulting in almost complete necrosis of the embolized liver 
parenchyma. The results obtained in this study confirmed that this was achieved. The 
EVAL/ethanol mixture has low viscosity, and has the advantage of having a non-adhesive property 
as opposed to N-butyl-2-cyanoacrylate (NBCA). Because of these features, the EVAL/ethanol 
mixture was considered to be able to flow into the portal vein and even into the sinusoids through 
the PBP. Moreover, by injecting while blocking the hepatic artery flow, the amount of blood mixed 
with the EVAL/ethanol mixture was decreased, and it was considered that there was an effect of 
prolonging the solidification time of EVAL. However, it could not be analyzed how much of the 
EVAL/ethanol mixture actually passed through hepatic sinusoids and reached the pulmonary 
capillary vessels. The oxygen saturation level was monitored and no significant deterioration was 
observed during the procedure, but further investigation is needed before embarking on clinical 
application.  
 Technically, by forcible injection, it was assumed that the risk of vessel rupture would 
increase resulting in insufficient embolization. However, the EVAL/ethanol mixture was visible by 
fluoroscopy, making it possible to control the injection pressure with safe injection of the embolic 
agent. In addition, no adhesion of the catheter to the arterial wall was observed, and it was pulled 
out after TAE without any problems in all animals. However, for future clinical application, it 
would be desirable to develop a more easily controllable way of forcible injection, as compared to 
manual, to achieve more consistent results and avoid under- or over-embolization. 
 As a fluid embolic agent, absolute ethanol has also been used in TAE for the treatment of 
some renal conditions, arteriovenous malformations and other pathologies in clinical practice (21, 
22). It may also flow into the portal veins and hepatic sinusoids following injection into the hepatic 
artery and damage them, resulting in hepatic segmental infarction. The mixture of ethiodized oil 
and absolute ethanol was previously used in subsegmental TAE for HCCs, but the embolic effect 
was not superior to that of conventional TAE with ethiodized oil followed by particulate embolus 
without consistent segmental infarction (3). The reason why segmental infarction was not achieved 
might be the immediate capillary blockage induced in PBP and terminal arterioles by absolute 
ethanol. Therefore, TAE with absolute ethanol was not employed in this study. A small amount of 
ethanol was contained as a solvent in the embolic material and a small amount of 30% ethanol was 
injected immediately before the EVAL/ethanol mixture injection in this study. However, no definite 
changes typically seen in ethanol embolization such as severe endothelial damages or perivascular 
inflammatory changes were observed, as also reported by Hamada et al. (14, 21). Therefore, the 
embolic effect of ethanol in this study was considered to be minimal. 
 This study has a number of limitations. The sample population was relatively small and the 
livers were normal rather than cirrhotic or tumorous. Passage of EVAL into the pulmonary 
circulation was not directly evaluated. It should be noted, EVAL/ethanol was not commercially 
available to the investigators and its use was limited under permission of individual institutional 
ethics committees. However, this embolic material is essentially the same as commercially 
available Onyx which was however unavailable in Japan where this study was perform. Despite 
these limitations, this preliminary study successfully demonstrated the feasibility of the technique 
and the need for further evaluation. 
 In conclusion, the transcatheter embolization by forcible intra-arterial injection of 
EVAL/ethanol mixture under micro-balloon occlusion was feasible and achieved the simultaneous 
embolization of hepatic artery, portal vein and hepatic sinusoids in swine liver for a prolonged 
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Figure 1. Representative angiogram from EVAL group. (a) Base line angiogram of the portal vein 
shows subsegmental branches (I, II, III). (b) Common hepatic arteriography also shows three major 
subsegmental branches corresponding to I, II and III. (c) The subsegmental hepatic arteriogram 
corresponds to II. Forcible intra-arterial injection of EVAL/ethanol mixture under micro-balloon 
occlusion was performed from this subsegmental hepatic artery. (d) Arterial portography performed 
immediately after embolization shows that the portal vein in the embolized segments (II) is 
occluded (arrow). (e) Arterial portography performed four weeks after embolization shows that the 
portal vein in the embolized segments (II) remains occluded. (f) Common hepatic arteriography 
performed four weeks after embolization shows that the embolized hepatic artery (II) is not re-
canalized. 
 
Figure 2. Photomicrograph (Hematoxylin-eosin stain, original magnification x200) of the 
embolized segment from EVAL group euthanized immediately after embolization. (a) EVAL is 
visualized as pale pink in this staining and fills the hepatic arteries (long arrow) and portal veins 
(short arrows). (b) The hepatic sinusoids are diffusely dilated with diffuse EVAL filling (arrows). 
 
Figure 3. (a) Gross specimen from the same EVAL case as seen in Figure 1 shows marked atrophy 
of the embolized subsegment with capsular retraction due to fibrotic changes (arrows). (b) 
Photomicrograph (Hematoxylin-eosin stain, original magnification x100) from the embolized 
segment shows a ghostly appearance of the hepatocytes indicating coagulation necrosis. EVAL fills 
the hepatic artery, portal vein, and hepatic sinusoids (arrows).  
 
Figure S1. Representative angiogram from ethiodized oil group. (a) Base line angiogram of the 
portal vein shows two subsegmental branches (I, II). (b) Arterial portography performed 
immediately after embolization of the subsegmental artery corresponding to II shows that the portal 
vein in the embolized segments is occluded (arrow). (c) Four weeks after embolization, arterial 
portography shows that the embolized portal vein (II) is restored (arrow). 
 
Figure S2. Representative angiogram from microspheres group. (a) Base line angiogram of the 
portal vein, shows two subsegmental branches (I, II). (b, c) Arterial portography performed 
immediately after embolization (b) and four weeks after embolization (c) of the subsegmental artery 
corresponding to II shows no obliteration of II. 
 
Figure S3. (a) Gross specimen from the same microspheres case as seen in Figure S2 shows no 
evidence of atrophy or fibrosis. (b) Photomicrograph (Hematoxylin-eosin stain, original 
magnification x100) shows microspheres filling only the hepatic artery (short arrows), not the portal 















Table 1. Summary of angiographic findings and parenchymal necrosis 
   Angiographic findings of embolized segment  
   Immediately after embolization  After follow up  
Group Animal No. 
Follo
w up  Hepatic artery Portal vein  Hepatic artery Portal vein 
Parenchymal 
necrosis 
EVAL 1 0 Occluded Occluded  N/A N/A N/A 
 2 0 Occluded Occluded  N/A N/A N/A 
 3 4wk. Occluded Occluded  Occluded Occluded Diffuse 
 4 4wk. Occluded Occluded  Occluded Occluded Diffuse 
 5 4wk. Occluded Occluded  Occluded Occluded Diffuse 
ethiodized oil 6 4wk. Occluded Occluded  Re-canalized Re-canalized None 
 7 4wk. Occluded Occluded  Re-canalized Re-canalized None 
microspheres 8 4wk. Occluded No change  Occluded No change None 
 9 4wk. Occluded No change  Occluded No change None 
 
EVAL; transcatheter arterial embolization (TAE) with a mixture of ethylene vinyl alcohol copolymer and ethanol mixture (EVAL/ethanol mixture) 
under micro-balloon occlusion 
ethiodized oil; TAE with simple intra-arterial injection of ethiodized oil without balloon occlusion 
microspheres; TAE with simple intra-arterial injection of microspheres without balloon occlusion 
 
 
Table 2.  Vascular distribution of EVAL in microscopic specimens 
Location Number of vessels and lobules 
 Total EVAL materials were present 
animal No.1   
Hepatic artery 348 297 (85%) 
Portal vein 348 282 (81%) 
Hepatic lobules 820 820 (100%) 
animal No.2   
Hepatic artery 183 174 (95%) 
Portal vein 177 160 (90%) 
Hepatic lobules 274 274 (100%) 
 
Number of vessels; the number of vessels where visible embolicmaterials were present on the microscopic sections of four square 
centimeters near the proximal portion of the embolized subsegmental artery 
Number of lobules; the number of hepatic lobules where the embolic materials were present more than 80% of the sinusoid area at 
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